Lymphocyte Transplantation Profile
Ordering Recommendation

Intended for TRANSPLANT patients only.

Quantitative Flow Cytometry
Within 24 hours
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Time SensitiveTime Sensitive
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Draw specimen before administering immunosuppressive medications. 
Green (sodium or lithium heparin), lavender (EDTA) or pink (K2EDTA). 
Specimen Preparation
Transport 5 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Clotted, hemolyzed, frozen, or refrigerated specimens. Specimens older than 48 hours.
New York State Clients: 
Clotted, hemolyzed, frozen, or refrigerated specimens. EDTA specimens older than 30 hours and heparin specimens older than 48 hours. 
Specimens must be analyzed within 48 hours of collection. Some medications may affect immunophenotyping results and should be listed on the patient test request form.
THIS TEST IS FOR TRANSPLANT PATIENTS ONLY. WBC and lymphocyte percent results with the same draw date and time as the Lymphocyte Transplantation Profile specimen must be provided by client.
New York State Clients: 
EDTA specimens must be analyzed within 30 hours of collection.  Heparin specimens must be analyzed within 48 hours of collection. 
Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
New York State Clients:
Ambient: 30 hours in EDTA, 48 hours in heparin; Refrigerated: Unacceptable; Frozen: Unacceptable 
Reference Interval
Effective November 18, 2013
Reports include age appropriate reference intervals and interpretation.
0-11 months
12-23 months2 years and older
% CD255-88 %55-88 %72-93 %
Absolute CD23800-5300 cells/µL3100-4200 cells/µL820-2800 cells/µL
% CD358-85 %53-81 %59-86 %
Abs CD32170-6500 cells/µL1460-5440 cells/µL650-2500 cells/µL
% CD438-62 %31-54 %30-63 %
% CD816-34 %16-38 %14-46 %
CD4: CD8 ratio1.17-6.621.17-6.620.70-4.00
% CD1911-45 %11-45 %6-23 %

Interpretive Data
In this test, the percent CD3 cells are those cells that are positive for both CD3 and the alpha-beta chain of the T-cell receptor and are presumed immunologically competent.

Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.

Immunosuppressive therapy with anti-lymphocyte drugs, such as OKT3 or ATG (anti-thymocyte globulin), can be monitored with this test.  For immunocompromised patients, order Lymphocyte Subset Panel 5 - Total Lymphocyte Enumeration (ARUP test code 0095892).
Component Test Code*Component Chart NameLOINC
0095248% CD3+/A-B+8124-0
0095249Absolute CD3+/A-B+8122-4
0095905% CD48123-2
0095910% CD832518-3
0095914% CD1920593-0
0095920CD4:CD8 Ratio54218-3
0095930% CD220594-8
0095931Absolute CD29557-0
0097135White Blood Cell Count6690-2
0097140% Lymph26478-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Immunosuppressive therapy monitoring
  • Post Transplant CD2 and CD3 Monitoring, Percent and Absolute